Lung cancer is the leading cause of cancer-related death worldwide, with approximately 1.2
million deaths annually. The standard-of-care in patients with advanced disease is platinum …

Background Due to extensive literature in the field of lung cancer and their heterogeneous
results, the aim of this study was to systematically review of systematic reviews studies which …

Introduction Lung cancer, the most prevalent malignant cancer in the world, remains a
serious threat to public health. Recently, a large number of studies have shown that an …

Background Non-small cell lung cancer (NSCLC) imposes a substantial burden on patients,
health care systems and society due to increasing incidence and poor survival rates. In …

Lung cancer remains the leading cause of cancer-related death and economic burden
worldwide. Despite the heavy toll of lung cancer, multiple new advances have improved …

Background Over the last 15 years, a paradigm shift in oncology has led to the approval of
dozens of targeted oral anti-cancer medications (OAMs), which have become the standard …

Background Maintenance gefitinib significantly prolonged progression-free survival (PFS)
compared with placebo in patients from eastern Asian with locally advanced/metastatic non …

During these last years, there have been an increased number of new drugs for non-small
cell lung cancer (NSCLC), with a growing financial effect on patients and society. The …

Objective To review and assess the quality of the available evidence on the cost-
effectiveness of erlotinib in the first-line treatment of advanced non-small cell lung cancer …

Background First-line maintenance erlotinib in patients with locally advanced or metastatic
nonsmall cell lung cancer (NSCLC) has demonstrated significant overall survival and …